Literature DB >> 17561141

A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy.

Brian R Lane1, Denise Babineau, Michael W Kattan, Andrew C Novick, Inderbir S Gill, Ming Zhou, Christopher J Weight, Steven C Campbell.   

Abstract

PURPOSE: Small renal masses are increasing in incidence. Most tumors 7 cm or less are treated with radical or partial nephrectomy but clinicians are increasingly relying on ablative therapies and observation for some small renal masses. We present novel nomograms that predict the likelihood of benign, likely indolent or potentially aggressive pathological findings based only on readily identifiable preoperative factors.
MATERIALS AND METHODS: Information on all partial nephrectomies performed at a single institution was collected in an institutional review board approved registry. Using retrospectively collected data on all 862 patients who underwent partial nephrectomy for a single, solid, enhancing, clinical T1 (7 cm or less) tumor between 1999 and 2005 tumors were classified as benign or malignant. Grade 3 clear cell renal cell carcinoma, grade 4 renal cell carcinoma of any type and any renal cell carcinoma with vascular, fat or collecting system invasion were considered potentially aggressive. The likelihood of benign, likely indolent or potentially aggressive pathological findings was modeled using multivariable logistic regression models based on age, gender, radiographic tumor size, symptoms at presentation and smoking history.
RESULTS: Of 862 small renal masses 20% were benign and 80% were malignant but only 30% of cancers (24% of small renal masses) were potentially aggressive. All 11 patients with systemic symptoms had cancer. The remaining 851 patients underwent further analysis. Factors that were most strongly associated with the likelihood of benign pathology were age, gender, tumor size and smoking history. A nomogram constructed to predict benign histology proved to be relatively accurate and discriminating (bootstrap corrected concordance index 0.644) and calibrated. Small renal masses in older men and younger women were more likely to be benign. With regard to differentiating indolent from potentially aggressive cancers, only advanced age was independently significant on multivariate analysis (p <0.005). The nomogram for this outcome performed with limited ability (concordance index 0.557).
CONCLUSIONS: Clinical factors provide substantial predictive ability to predict benign vs malignant pathology for small renal masses amenable to partial nephrectomy. Although most of these small renal masses are benign or indolent, our ability to predict potentially aggressive cancer in this population remains limited.

Entities:  

Mesh:

Year:  2007        PMID: 17561141     DOI: 10.1016/j.juro.2007.03.106

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  61 in total

1.  Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases.

Authors:  Andrea Veltri; Irene Garetto; Irene Tosetti; Marco Busso; Alessandro Volpe; Donatella Pacchioni; Enrico Bollito; Mauro Papotti
Journal:  Eur Radiol       Date:  2010-09-01       Impact factor: 5.315

2.  Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors.

Authors:  Boyd R Viers; R Houston Thompson; Christine M Lohse; John C Cheville; Bradley C Leibovich; Stephen A Boorjian; Matthew K Tollefson
Journal:  World J Urol       Date:  2016-04-06       Impact factor: 4.226

3.  Active surveillance for small renal masses.

Authors:  Phillip M Pierorazio; Elias S Hyams; Jeffrey K Mullins; Mohamad E Allaf
Journal:  Rev Urol       Date:  2012

4.  Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.

Authors:  Brandon J Manley; Ed Reznik; Mazyar Ghanaat; Mahyar Kashan; Maria F Becerra; Jozefina Casuscelli; Daniel Tennenbaum; Almedina Redzematovic; Maria I Carlo; Yusuke Sato; Maria Arcila; Martin H Voss; Darren R Feldman; Robert J Motzer; Paul Russo; Jonathan Coleman; James J Hsieh; Ari A Hakimi
Journal:  Urol Oncol       Date:  2017-11-11       Impact factor: 3.498

5.  External validation of the RENAL nephrometry score nomogram for predicting high-grade renal cell carcinoma in solid, enhancing, and small renal masses.

Authors:  Kyo Chul Koo; Hanna Yoo; Tae Young Shin; Jongchan Kim; Young Deuk Choi; Koon Ho Rha; Won Sik Ham
Journal:  World J Urol       Date:  2013-09-07       Impact factor: 4.226

6.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

7.  Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis.

Authors:  Mark W Ball; Michael A Gorin; Sam B Bhayani; Craig G Rogers; Michael D Stifelman; Jihad H Kaouk; Homayoun Zargar; Susan Marshall; Jeffrey A Larson; Haider M Rahbar; Bruce J Trock; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Urol Oncol       Date:  2014-12-11       Impact factor: 3.498

Review 8.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

9.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

10.  Transplantation of kidneys with small renal tumors: A novel idea?

Authors:  Sameer Grover; Samiran Das Adhikary; Nitin Kekre
Journal:  Indian J Urol       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.